To test whether HDGF could increase oligodendrocyte genesis via NCL, SVZ OPCs were differentiated in the presence of VC with non-specific isotype-matched IgG, or HDGF with non-specific isotype-matched IgG or NCL-specific function blocking antibody, which was previously used at 5-10 μg/ml to block HDGF uptake in cancer cells (Chen et al., 2015; Lin et al., 2019) (Figure 7C). This evidence concerns the gene HDGF and cancer.